3 Under-the-Radar Biotech Stocks to Buy in 2022
Beam Therapeutics is different from many CRISPR-editing biotechs in that it uses ex-vivo base cell editing instead of nuclease cell editing. Beam stock is down more than 48% so far this year, but the company has a growing pipeline that shows promise. Its lead therapy is BEAM-101 to treat various blood diseases, including sickle cell disease (SCD) and beta thalassemia.